This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Author Affiliations
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Mental Health, Johns Hopkins University School of Public Health, Baltimore, Maryland
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
- These authors contributed equally.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Mental Health, Johns Hopkins University School of Public Health, Baltimore, Maryland
- These authors contributed equally.
- Corresponding author: Paul S. Nestadt, MD, 600 N Wolfe St, Meyer 114, Baltimore, MD 21287 ([email protected]).
References (32)
- Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28. PubMed CrossRef
- Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170(3):324–333. PubMed CrossRef
- Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–253. PubMed CrossRef
- Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry. 1997;170(3):205–228. PubMed CrossRef
- Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. PubMed CrossRef
- Nucifora FC Jr, Woznica E, Lee BJ, et al. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. PubMed CrossRef
- Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992;18(3):515–542. PubMed CrossRef
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. PubMed CrossRef
- McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610. PubMed CrossRef
- Siskind D, McCartney L, Goldschlager R, et al. Clozapine vs first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392. PubMed CrossRef
- Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018;201:10–19. PubMed CrossRef
- Cotes RO, Janjua AU, Broussard B, et al. A comparison of attitudes, comfort, and knowledge of clozapine among two diverse samples of US psychiatrists. Community Ment Health J. 2022;58(3):517–525. PubMed CrossRef
- Nucifora FC Jr, Mihaljevic M, Lee BJ, et al. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750–761. PubMed CrossRef
- Lee BJ, Marchionni L, Andrews CE, et al. Analysis of differential gene expression mediated by clozapine in human postmortem brains. Schizophr Res. 2017;185:58–66. PubMed CrossRef
- Nucifora FC Jr, Baker KK, Stricklin A, et al. Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study. Schizophr Res. 2021;229:134–136. PubMed CrossRef
- Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152(2):183–190. PubMed CrossRef
- Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627. PubMed CrossRef
- Taipale H, Tanskanen A, Mehtälä J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. PubMed CrossRef
- Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et al. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res. 2013;150(1):274–280. PubMed CrossRef
- Munro J, O’Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999;175(6):576–580. PubMed CrossRef
- Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv. 1998;49(8):1029–1033. PubMed CrossRef
- Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry. 2005;66(4):534–538. PubMed CrossRef
- Spivak B, Shabash E, Sheitman B, et al. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003;64(7):755–760. PubMed CrossRef
- Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2-3):139–145. PubMed CrossRef
- Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91. PubMed CrossRef
- Kapusta ND, Tran US, Rockett IR, et al. Declining autopsy rates and suicide misclassification: a cross-national analysis of 35 countries. Arch Gen Psychiatry. 2011;68(10):1050–1057. PubMed CrossRef
- Stone DM, Holland KM, Bartholow B, et al. Deciphering suicide and other manners of death associated with drug intoxication: a Centers for Disease Control and Prevention consultation meeting summary. Am J Public Health. 2017;107(8):1233–1239. PubMed CrossRef
- Liu D, Yu M, Duncan J, et al. Discovering the unclassified suicide cases among undetermined drug overdose deaths using machine learning techniques. Suicide Life Threat Behav. 2020;50(2):333–344. PubMed CrossRef
- Rockett IRH, Caine ED, Connery HS, et al. Unrecognised self-injury mortality (SIM) trends among racial/ethnic minorities and women in the USA. Inj Prev. 2020;26(5):439–447. PubMed CrossRef
- Pamer C, Serpi T, Finkelstein J. Analysis of Maryland poisoning deaths using classification and regression tree (CART) analysis. Presented at the AMIA Annual Symposium Proceedings. 2008:550; American Medical Informatics Association.
- Nielsen J, Young C, Ifteni P, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149–161. PubMed CrossRef
- Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in medicaid. Am J Manag Care. 2012;18(3):e109–e117. PubMed
